- Conditions
- Focal Segmental Glomerulosclerosis
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 12 Years to 64 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- New Hyde Park, New York • Chapel Hill, North Carolina • Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
- Interventions
- FG-3019, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 28
- States / cities
- Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Pamrevlumab, Placebo, Corticosteroids
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 24
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 21 more
- Conditions
- Pancreatic Cancer Non-resectable
- Interventions
- Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 28 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 20 more
- Conditions
- Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
- Drug
- Lead sponsor
- Pancreatic Cancer Action Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Diabetes Mellitus, Diabetic Nephropathy
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 15 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 35 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • New Haven, Connecticut + 15 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Pamrevlumab
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
- Conditions
- Diabetes Mellitus
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Dallas, Texas + 2 more
- Conditions
- COVID-19
- Interventions
- Pamrevlumab, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Ann Arbor, Michigan • Dallas, Texas + 1 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
- Conditions
- Locally Advanced or Metastatic Pancreatic Cancer
- Interventions
- FG-3019
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 7
- States / cities
- Stanford, California • Lebanon, New Hampshire • Cleveland, Ohio + 4 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Pamrevlumab, Placebo, Corticosteroids
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 6 Years to 11 Years · Male only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 24 more
- Conditions
- Pancreatic Cancer (Unresectable)
- Interventions
- FG-3019, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more